| Bioactivity | VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1]. |
| CAS | 815592-21-3 |
| Formula | C27H34N4O4S |
| Molar Mass | 510.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Van Goor F, et al. Rescue of ﾎ認508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2006, 290(6): L1117-L1130. |